|Bid||1.9000 x 1000|
|Ask||2.2000 x 1000|
|Day's Range||1.9000 - 1.9500|
|52 Week Range||1.8600 - 5.1000|
|Beta (3Y Monthly)||2.13|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.40|
SAN DIEGO, March 15, 2019 -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2018 and provided a business.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 14) Novartis AG (NYSE: NVS ) (announced resignation of ...
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review the company’s New Drug Application (“NDA”) for its higher naloxone injection product candidate for the treatment of opioid overdose. On March 14, 2019, Adamis received FDA correspondence relating to the company’s NDA stating that the Agency had completed its filing review and had determined that the NDA was sufficiently complete to permit a substantive review. The FDA further provided a target agency action date of October 31, 2019.
Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you own shares in Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measureRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 26) AstraZeneca plc (NYSE: AZN )(announced positive results ...
Adamis Pharmaceuticals Corporation (ADMP) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for its sublingual tadalafil product. As previously announced, on December 28th, 2018, Adamis submitted an NDA for fast-disintegrating sublingual tadalafil (APC-8000) with the FDA for the treatment of erectile dysfunction (ED). Upon its preliminary review, the FDA determined that the submitted NDA was not sufficiently complete to permit a substantive review.
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) announced today that the article entitled “Higher doses of naloxone are needed in the synthetic opioid era” has been published in the peer reviewed journal Substance Abuse Treatment, Prevention, and Policy. The article notes the dramatic increase in deaths due to illicit use of the opioid fentanyl, reviews the literature on the number of repeat doses of naloxone to treat fentanyl overdoses, reviews the pharmacology of naloxone and fentanyl, and provides a rationale for using higher doses of naloxone as an effective countermeasure.
Dennis Carlo became the CEO of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) in 2009. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 16) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioDelivery ...
NEW YORK, NY / ACCESSWIRE / January 17, 2019 / Despite concerns of a partial government shutdown, U.S. markets extended gains for the second consecutive session on Wednesday on strong earnings from Bank ...
Adamis Pharmaceuticals Corporation (ADMP) today announced that its marketing and commercial partner, Sandoz Inc. (Sandoz), a Novartis division, has launched SYMJEPI™ (epinephrine) 0.3 mg Injection in the US market for the emergency treatment of allergic reactions (Type 1), including anaphylaxis. SYMJEPI will be rolled out via a phased launch and will initially be available in the institutional setting, an established channel where Sandoz Inc. has significant experience and knowledge, followed by introduction into the retail market.
NEW YORK, Jan. 03, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) announced its NDA filing Friday for a fast-dissolving sublingual tadalafil tablet for erectile dysfunction. The Analyst Raymond James analyst Elliot Wilbur maintained ...
Adamis Pharmaceuticals Corporation (ADMP) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its naloxone pre-filled single dose syringe (PFS) product candidate. This injection is designed for the treatment of an opioid overdose. Adamis submitted the NDA pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act.
From data-based care solutions to improved treatment options, Premier Health Group (PHGRF) (PHGI), Rite Aid Corporation (RAD), Adamis Pharmaceuticals Corp (ADMP), and Synergy Pharmaceuticals Inc (SGYP) are 4 pharma stocks heating up on Monday. Synergy Pharmaceuticals, Inc (SGYP) a biopharmaceutical company that is largely focused on developing originative gastrointestinal therapies, announced earlier this month that it had entered into an agreement with Bausch Health Companies Inc. through which Bausch Health would acquire substantially all of Synergy's assets, including all rights to TRULANCE®,dolcanatide and related intellectual property, for approximately $200 million in cash.
Adamis Pharmaceuticals Corporation (ADMP) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its fast-dissolving sublingual tadalafil tablet. This product candidate is designed for the treatment of erectile dysfunction. Adamis submitted the NDA pursuant to Section 505(b)(2) of the Food, Drug & Cosmetic Act.
Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.
Novartis AG said its U.S. unit Sandoz Inc will launch Adamis Pharmaceuticals Corp's emergency allergy shots next year in the United States, at a price that is about 16 percent below that of similar rival products. Sandoz will start selling the pre-filled epinephrine syringes, SYMJEPI, in the United States in the first quarter of 2019 at a wholesale price of $250 for a two-pack of 0.3 mg injections, Novartis said in a statement.
Adamis Pharmaceuticals Corporation (ADMP) today provided a business update announcing the U.S. launch of FDA-approved SYMJEPI ™ (epinephrine) 0.3mg Injection is planned for early Q1 2019. Adamis has continued to work closely with Sandoz Inc., a Novartis division, which has exclusive rights to market and distribute Symjepi in the U.S., to prepare for the U.S. market introduction of this life-saving treatment. Manufacture of commercial batches has been completed and Adamis will begin shipping to Sandoz distribution centers during December to ensure the appropriate supply for launch. SYMJEPI (epinephrine) 0.3mg Injection is indicated for the emergency treatment of allergic reactions (Type 1), including anaphylaxis, to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances and other allergens, as well as idiopathic or exercise-induced anaphylaxis.
Teva (TEVA) launches the first approved generic version of Mylan's (MYL) popular EpiPen (epinephrine) auto-injector for severe allergy treatment in the United States.
Adamis (ADMP) delivered earnings and revenue surprises of -40.00% and -28.83%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of 21 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...